The market for multiplex biomarker imaging is anticipated to reach a valuation of USD 1,631.4 million by 2034, up from USD 585.0 million in 2024. The projected CAGR for sales between 2024 and 2034 is 10.8%. In 2023, the industry brought in USD 532.8 million in revenue.
Advanced technology in high throughput imaging systems makes it possible to precisely investigate multiple biomarkers at once, increasing the precision and effectiveness of diagnosis. The rise in complex diseases like cancer and neurological conditions necessitates a thorough examination of biomarkers, which is crucial for developing tailored treatments.
For the companies in the multiplex biomarker imaging market, combining multiplex biomarker imaging with next generation sequencing (NGS) technologies presents a significant opportunity.
Combining the new tools can result in a more thorough understanding of the molecular underpinnings of disorders, enabling more precise and customized treatment plans. This collaboration is particularly helpful in the field of cancer, as the identification of genetic anomalies and the corresponding protein expressions might result in improvements in targeted treatment.
As new biomarkers continue to be discovered, there is a growing need for better imaging systems that can accurately detect and quantify the markers. Because of this need, businesses have the chance to innovate and produce new imaging platforms and reagents that are tailored to the evolving biomarkers, expanding their product lines and market penetration.
Competitive Landscape
The multiplex biomarker imaging market competitive landscape is mildly competitive, with top companies pushing innovation. Potential investment opportunities in multiplex biomarker imaging technology and service providers with applications ranging from cancer to immunology and neurology.
Emerging players and strategic collaborations ratchet up competition, pushing the limits of precision medicine and driving fast advances in biomarker detection and analysis.
Company websites and investor presentations of leading players in the industry are anticipated to bring industry investment potential, which will in turn help the key players face multiplex biomarker imaging industry challenges. This will also boost the leading players in the industry and their industry share.
Recent Industry Developments
- In May 2024, llumina Inc. announced that part of their latest research would be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4. Highlights include data from several studies in partnership with Labcorp, demonstrating additional evidence to support the use of comprehensive genomic profiling (CGP) over single gene testing (SGT) and the most recent data supporting the development of Illumina’s molecular residual disease (MRD) assay, which is currently underway in collaboration with major In all, Illumina had 14 abstracts accepted for the conference.
- In April 2024, Merck intends to purchase Mirus Bio for USD 600 million. Mirus Bio, based in Madison, Wisconsin, focuses on the development and sale of transfection reagents. Transfection reagents, including Mirus Bio’s TransIT-VirusGEN®, help genetic material enter cells. The compounds are essential in the creation of viral vectors for cell and gene therapies.
Leading Multiplex Biomarker Imaging Brands
- PerkinElmer Inc.
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Abcam plc.
- Merck KGaA
- Illumina Inc.
- Leica BiosystemsNussloch GmbH
- Ventana Medical Systems, Inc.
- AushonBioSystems Ltd.
- MicroConstants, Inc.
- ToposNomos Ltd.
Access the Full Report
Key Segments of the Report
By Component Type:
The multiplex biomarker imagining industry is classified into instruments (quantitative pathology imaging system, immunofluorescence, multispectral imaging system and toponome imaging system), software and services (installation and integration services and maintenance services).
By Imaging Technique:
The multiplex biomarker imagining industry is classified into Immunohistochemistry (IHC) Assay, Fluorescent in Situ Hybridization (FISH) Assay and Tissue Microarray (TMA) Assay).
By Application:
The multiplex biomarker imagining industry is classified into research and clinical diagnostics.
By End User:
The multiplex biomarker imagining industry is classified into translation laboratories, biopharmaceutical companies and academic institutes.
By Region:
Analysis of the multiplex biomarker imagining industry has been carried out in key countries of North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe and Middle East & Africa.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
